BergenBio Fundamentale Forhold (BGBIO)

[Morgo26]

Probably end tomorrow in minus as well

[Borup19]

Det betyder vel, at setup og aftaler er på plads med x antal hospitaler i Indien!?

[Toxern]

25kr før helga?

[lasseht]

25 pluss nåværende kurs

[guz]

hallelujah

[Zydenboy]

Det er vel ingen i markedet som ikke trodde at man skulle få denne godkjennelsen i India på bakgrunn at det er kjent at søknaden er inne. Og godkjennelse er allerde gitt i UK og SA. Virker som det eneste som gir push oppover er faktisk at doseringen faktisk virker. I den senere tid så gir slike nyheter en push oppover tidlig på børsdagen for så å falle igjen utover dagen og neste dag igjen. Det er bare begynnelsen på en rekke nyheter i Q4 og begynnelsen av 2021.

[Londonmannen]

Tror heller ikke at gårsdagens nyhet vil gi noe vesentlig og varig løft i aksjekursen. Om så skjer vil det overraske meg. Det jeg nå venter på, og det vil ta en måned eller to før vi får, er signaler om at Bemcentinib har positiv virkning. Da vil kursen begynne en himmelferd det blir vanskelig å si hvor ender. Men et oppkjøp vil være nærliggende dersom så skjer. Samtidig må man være forberedt på at ledelsen, i verste fall, tok feil da de uttrykte sin optimisme. For shit happens. Spesielt innen farmasisegmentet. Invester med hodet og ikke med hjertet.

[eiken]

Får håpe på effekt da. Kjiip sykdom og behov for hjelp, får håpe det går raskt med rekrutering. Betennelser på hjerte, bukspyttkjertel, lungekollaps og nervebetennelser. Haster med å finne noe som hjelper.

[Tekspert]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @Multiple (249 likes)

BergenBio Småprat (BGBIO)

Noen poenger når det gjelder utvidelsen av studien av bemcentinib til kombinasjon med dexamethason og remdesivir.

2. @Evilfreud (182 likes)

BergenBio Småprat (BGBIO)

Foreslår vi kjører en mer hyggelig tone. Er heldigvis mulig å dempe folk.

3. @Londonmannen (173 likes)

BergenBio Småprat (BGBIO)

Ny dag og nye muligheter. En dag nærmere både det ene og det andre, men viktigst som BGBIO aksjonær er nok at vi går mot en avklaring i Bemcentinib sin rolle ifm Covid-19.

Resten av topp 10:

4. @Ekornet (153 likes)

5. @Dweller (139 likes)

6. @vcp (129 likes)

7. @Fornybar (120 likes)

8. @drdr (111 likes)

9. @Flottesen (111 likes)

10. @Timm (108 likes)

Gratulerer!

[HeldigFyr]

[TekBot]

BERGENBIO ANNOUNCES FIRST PATIENT DOSED WITH BEMCENTINIB IN RELAPSED MALIGNANT PLEURAL MESOTHELIOMA INVESTIGATOR SPONSORED PHASE IIA STUDY

Bergen, Norway, 7 October 2020 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, announces that the first patient has been dosed and
…

Vis børsmeldingen

continues on therapy in a trial assessing bemcentinib in relapsed malignant
mesothelioma patients, sponsored by the University of Leicester.

With the support of the British Lung Foundation, which has provided £2.5 million
in funding, the University of Leicester is leading the development of the
world’s first molecularly stratified umbrella study in mesothelioma named
Mesothelioma Stratified Therapy (MiST). The goal of MiST is to enable the
acceleration of novel, effective personalised therapy as a basis for improving
survival outcomes for patients with mesothelioma. The current study assessing
bemcentinib, MiST3, is a part of this umbrella study and is an all-comers arm,
with no requirement for molecular markers for eligibility.

MiST3 is a two-stage, single-arm Phase IIa clinical trial of bemcentinib and
pembrolizumab for the treatment of relapsed malignant pleural mesothelioma
patients. The study will enroll up to 26 patients at three sites in the United
Kingdom. The primary endpoint of this trial is disease control rate at 12 weeks,
with an analysis of complete or partial responses in patients. Other endpoints
include safety and toxicity, objective response rate, and disease control rate
at 24 weeks for bemcentinib in combination with pembrolizumab.

More information about the trial can be found
here (https://clinicaltrials.gov/ct2/show/NCT03654833).

AXL is over-expressed in many solid tumours, including malignant pleural
mesothelioma (MPM). Within mesothelioma, AXL expression has been shown in 74% of
tissue samples analysed[1]. AXL has also been implicated in epithelial-to
-mesenchymal transition (EMT), which promotes metastasis and the ability of
cells to migrate through extracellular matrix and intravasate into blood
vessels[2]. A strong association between EMT status and an inflammatory tumour
micro-environment with an elevation of multiple targetable immune checkpoint
molecules has been previously shown[3]. Bemcentinib has been shown to enhance
the efficacy of checkpoint inhibitors, such as pembrolizumab, in preclinical
cancer models and in patients with lung cancer (SITC 2019). Key effects of
bemcentinib in this setting include activation of innate immunity in the tumour
microenvironment, leading to activation of adaptive anti tumour T cell
responses.

Professor Gavin Murphy, Director of the Leicester Clinical Trials Unit,
commented:

“Leicester Clinical Trials Unit are delighted to announce the opening and
recruitment of the first participant to this important Phase IIa study. The
collaboration includes the British Lung Foundation, BerGenBio, University of
Leicester Professors Anne Thomas and Professor Dean Fennell and Dr. Matthew
Krebs from The Christie, Manchester, and represents the culmination of three
years’ work. The ultimate output of this study will be the potential to provide
benefit to the MPM population.”

Richard Godfrey, Chief Executive Officer of BerGenBio, commented:

“We congratulate Professor Anne Thomas, Dr. Matthew Krebs and Professor Dean
Fennel on the start of this novel clinical study. We believe this trial can
provide an opportunity to potentially prolong the duration of response with a
combination of bemcentinib and pembrolizumab to patients who currently have no
standard option of care. With the UK having the highest global incidence of MPM,
several patients are likely to benefit from this trial recruiting in Manchester,
Leicester, and Newcastle. Data obtained from this trial will not only benefit
the UK population but also benefit the MPM population globally as a result of
the continued use of asbestos in the developing world.”

• END -

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive and therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad Phase II oncology clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing Phase I clinical testing. In parallel, BerGenBio is
developing companion diagnostic tests to identify those patient populations most
likely to benefit from bemcentinib or tilvestamab: this is expected to
facilitate more efficient registration trials and support a precision medicine
-based commercialisation strategy. For further information, please visit:
www.bergenbio.com (http://www.bergenbio.com)

About Investigator-Sponsored Trials

Investigator-sponsored clinical trials are clinical trials proposed by front
-line patient-facing physicians who act as the regulatory sponsor and are
supported by industry in bespoke clinical development partnerships. The industry
partner does not assume the role of sponsor according to European or US
regulatory guidelines but may offer support in a variety of different ways, such
as providing investigational medicinal product at no cost and providing
additional financial support as required.

About Malignant Pleural Mesothelioma

Malignant pleural mesothelioma (MPM) is a cancer that develops in the lungs.
The cause of pleural
mesothelioma (https://www.asbestos.com/mesothelioma/causes/) is exposure to
asbestos fibres (https://www.asbestos.com/exposure/), which are inhaled into the
lungs. It usually takes from 20 to 50 years for mesothelioma to develop after a
person’s first exposure to asbestos. Because of this latency period, the disease
usually affects people older than 75. (www.asbestos.com) In the UK, 65,000
people are expected to die by 2050 (after 2001), making mesothelioma one of the
few predicted cancer epidemics. The average life expectancy for pleural
mesothelioma (https://www.asbestos.com/mesothelioma/life-expectancy/) is often
less than 18 months.

For more information, please contact
Richard Godfrey
CEO, BerGenBio ASA
media@bergenbio.com
+47 917 86 304

International Media Relations

Mary-Jane Elliott, Chris Welsh, Carina Jurs,

Lucy Featherstone, Maya Bennison

Consilium Strategic Communications

bergenbio@consilium-comms.com

+44 7780 600290

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

1. D. J. Pinato, F. A. Mauri, T. Lloyd, V. Vaira, C. Casadio, R. L. Boldorini,
   and R. Sharma, “The expression of Axl receptor tyrosine kinase influences the
   tumour phenotype and clinical outcome of patients with malignant pleural
   mesothelioma.,” Br. J. Cancer, vol. 108, no. 3, pp. 621-628, Feb. 2013.

2. G. Mudduluru, P. Vajkoczy, and H. Allgayer, “Myeloid zinc finger 1 induces
   migration, invasion, and in vivo metastasis through Axl gene expression in solid
   cancer.,” Mol. Cancer Res., vol. 8, no. 2, pp. 159-169, Feb. 2010

3. Y. Lou, L. Diao, E. R. P. Cuentas, W. L. Denning, L. Chen, Y. H. Fan, L. A.
   Byers, J. Wang, V. A. Papadimitrakopoulou, C. Behrens, J. C. Rodriguez, P. Hwu,
   I. I. Wistuba, J. V Heymach, and D. L. Gibbons, “Epithelial-Mesenchymal
   Transition Is Associated with a Distinct Tumor Microenvironment Including
   Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung
   Adenocarcinoma.,” Clin. Cancer Res., vol. 22, no. 14, pp. 3630-3642, Jul. 2016.

Kilde

[TekBot]

BerGenBio kunngjør første pasient dosert med bemcentinib i tilbakevendende malignt pleuralt mesoteliom (lungehinnekreft) i sponset fase-IIa utprøvingsstudie

Bergen, Norge, 7 Oktober 2020 - BerGenBio ASA (OSE: BGBIO), et biofarmasøytisk
selskap i klinisk fase som utvikler nye, selektive hemmere av AXL-kinase for
krefttyper med behov for forbedret behandlingstilbud, kunngjør at første pasient
…

Vis børsmeldingen

er dosert og fortsetter behandlingen i en medisinsk studie som vurderer
bemcentinib hos pasienter med tilbakevendende ondartet malignt pleuralt
mesoteliom (lungehinnekreft). University of Leicester i UK er sponsor av
studien.

University of Leicester leder utviklingen av verdens første molekylær
stratifisert paraplystudie av mesoteliom kalt Mesothelioma Stratified Therapy
(MiST), med et finansielt bidrag fra The British Lung Foundation på 2,5
millioner GBP. MiST sitt mål er å muliggjøre en ny, effektiv personalisert
behandlingsform for å forbedre overlevelse hos pasienter med mesoteliom. Den
aktuelle studien MiST3 som evaluerer BerGenBios legemiddel bemcentinib, er en
del av paraplystudien, og er en «alle-inkludert» arm, uten krav til molekylære
markører for kvalifisering.

MiST3 er en to-trinns, enkelt-arm fase-IIa klinisk studie av bemcentinib og
pembrolizumab for behandling av pasienter med tilbakevendende malignt pleuralt
mesoteliom. Studien vil inkludere opp til 26 pasienter på tre behandlingssentere
i Storbritannia. Det primære endepunktet for denne studien er
sykdomsbekjempelsesrate etter 12 uker, hvor fullstendig eller delvis responsrate
hos pasienter blir analysert. Andre endepunkt inkluderer sikkerhet, objektiv
responsrate, og sykdomsbekjempelsesrate etter 24 uker for bemcentinib kombinert
med pembrolizumab.

Ytterligere informasjon om studien finnes her
(https://clinicaltrials.gov/ct2/show/NCT03654833)

AXL er funnet overuttrykt i mange solide svulster, inkludert malignt pleuralt
mesoteliom (MPM). I MPM er AXL påvist uttrykt i 74% av analyserte vevsprøver[1].
AXL driver «epithelial-to-mesenchymal transition» (EMT) i kreftceller noe som
igjen fremmer metastase (spredning) [2]. Det er funnet en sterk sammenheng
mellom kreftcellenes EMT status og et inflammatorisk mikromiljø karakterisert av
immunhemmende molekyler[3]. Bemcentinib er vist å forbedre effekten av
sjekkpunkthemmere, slik som pembrolizumab, i prekliniske kreftmodeller og hos
pasienter med lungekreft (jfr Krebs et al., SITC 2019). En viktig
virkningsmekanisme for bemcentinib er aktiveringen av medfødt immunitet (innate
immunity) i kreftens mikromiljø, noe som fører til aktivering av innlærte
(adaptive immunity) antitumor T-celleresponser.

Prof. Gavin Murphy, Direktør for Leicester Clinical Trials Unit, uttaler:

«Leicester Clinical Trials Unit er glade for å kunngjøre åpningen og
rekrutteringen av den første deltakeren i denne viktige fase-IIa studien.
Samarbeidet inkluderer The British Lung Foundation, BerGenBio, Prof. Anne Thomas
og Prof. Dean Fennell, University of Leicester, og Dr. Matthew Krebs fra The
Christie, Manchester og er et resultat av tre års forberedende arbeid. Det
ultimate målet med denne studien er å gi et bedre behandlingstilbud til
pasienter med MPM.»

Richard Godfrey, administrerende direktør i BerGenBio, uttaler:

«Vi gratulerer Prof. Anne Thomas, Dr. Matthew Kreb og Prof. Dean Fennel med
oppstarten av denne nye kliniske studien. Vi mener denne studien potensielt har
muligheten til å forlenge responsvarigheten gjennom en kombinasjon av
bemcentinib og pembrolizumab, for pasienter som for øyeblikket ikke har et
behandlingsalternativ. Siden Storbritannia har verdens høyeste forekomst av MPM
pasienter, er det sannsynlig at mange pasienter vil kunne dra nytte av at denne
studien rekrutterer pasienter fra Manchester, Leicester og Newcastle. Data fra
denne studien vil derimot ikke kun være til nytte for befolkningen i
Storbritannia, men vil også gagne pasienter globalt der MPM er et resultat av
fortsatt bruk av asbest i mange utviklingsland.»

• SLUTT -

Om BerGenBio ASA

BerGenBio er et klinisk fase biofarmasøytisk selskap som setter søkelys på å
utvikle transformative medisiner rettet mot AXL som en potensiell hjørnestein i
terapi for aggressive sykdommer, inkludert immununnvikende og
medikamentresistente kreftformer. Selskapets proprietære hovedkandidat,
bemcentinib, er en potensiell førsteklasses selektiv AXL-hemmer i et bredt fase
II onkologisk klinisk utviklingsprogram med fokus på kombinasjons- og
enkeltmiddelterapi i lungekreft, leukemi og COVID-19. Et førsteklasses
funksjonsblokkerende anti-AXL-antistoff gjennomgår klinisk fase I-tester.
Parallelt utvikler BerGenBio en «companion diagnostics» test for å identifisere
de pasientpopulasjonene som mest sannsynlig vil dra nytte av bemcentinib: dette
forventes å legge til rette for registreringsforsøk som støtter en
presisjonsmedisinbasert kommersialiseringsstrategi.

BerGenBio har base i Bergen, Norge med et datterselskap i Oxford, Storbritannia.
Selskapet er notert på Oslo Børs (ticker: BGBIO). For mer informasjon, besøk
www.bergenbio.com

Om Sponsede Utprøvingsstudier (Investigator-Sponsored Trials)

Sponsede utprøvingsstudier er kliniske studier foreslått av leger i
førstelinjetjeneste med pasientkontakt, som fungerer som reguleringssponsor og
støttes av industrien i skreddersydde kliniske utviklingspartnerskap.
Industripartneren påtar seg ikke rollen som sponsor i henhold til europeiske
eller amerikanske retningslinjer, men kan tilby støtte på en rekke forskjellige
måter, slik som å tilby utprøvingspreparater kostnadsfritt og tilby ytterligere
økonomisk støtte etter behov.

Om Malignt Pleuralt Mesoteliom (lungehinnekreft)

Malignt pleuralt mesoteliom (MPM) er en kreft som utvikles i lungene.
Sykdomsårsaken til pleuralt mesoteliom er knyttet til asbesteksponering, hvor
asbestfibrene er innåndet i lungene. Utviklingstiden for sykdommen er lang, fra
20 til 50 år, etter en person har vært eksponert for asbest første gang. På
grunn av latenstiden påvirker sykdommen vanligvis personer eldre enn 75 år
(www.asbestos.com). Et forventet antall dødsfall i Storbritannia på 65,000
personer innen år 2050 (etter 2001), gjør mesoteliom til en av de få
forutsigbare kreftepidemier. Gjennomsnittlig forventet levetid for pleuralt
mesoteliom er ofte mindre enn 18 måneder.

For ytterligere informasjon, vennligst kontakt

Richard Godfrey, administrerende direktør, BerGenBio ASA

media@bergenbio.com

+47 917 86 304

Internasjonal mediakontakt

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications

bergenbio@consilium-comms.com

+44 7780 600290

Fremtidsrettede uttalelser

Denne kunngjøringen kan inneholde fremtidsrettede uttalelser, som i seg selv
ikke er historiske fakta, men er basert på forskjellige antagelser, hvorav mange
er basert på ytterligere forutsetninger. Disse forutsetningene er i sin natur
underlagt betydelige kjente og ukjente risikoer, usikkerheter og andre viktige
faktorer. Slike risikoer, usikkerheter, betingelser og andre viktige faktorer
kan føre til at faktiske hendelser avviker vesentlig fra forventningene uttrykt
eller underforstått i denne kunngjøringen av slike fremtidsrettede uttalelser.

Denne opplysningen er informasjonspliktig etter verdipapirhandelloven § 5-12.

1. D. J. Pinato, F. A. Mauri, T. Lloyd, V. Vaira, C. Casadio, R. L. Boldorini,
   and R. Sharma, “The expression of Axl receptor tyrosine kinase influences the
   tumour phenotype and clinical outcome of patients with malignant pleural
   mesothelioma.,” Br. J. Cancer, vol. 108, no. 3, pp. 621-628, Feb. 2013.

2. G. Mudduluru, P. Vajkoczy, and H. Allgayer, “Myeloid zinc finger 1 induces
   migration, invasion, and in vivo metastasis through Axl gene expression in solid
   cancer.,” Mol. Cancer Res., vol. 8, no. 2, pp. 159-169, Feb. 2010

3. Y. Lou, L. Diao, E. R. P. Cuentas, W. L. Denning, L. Chen, Y. H. Fan, L. A.
   Byers, J. Wang, V. A. Papadimitrakopoulou, C. Behrens, J. C. Rodriguez, P. Hwu,
   I. I. Wistuba, J. V Heymach, and D. L. Gibbons, “Epithelial-Mesenchymal
   Transition Is Associated with a Distinct Tumor Microenvironment Including
   Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung
   Adenocarcinoma.,” Clin. Cancer Res., vol. 22, no. 14, pp. 3630-3642, Jul. 2016.

Kilde

[TekBot]

BERGENBIO PRESENTS DATA ON ANTI-AXL ANTIBODY TILVESTAMAB AT 32[nd] ENA SYMPOSIUM

Bergen, Norway, 14 October 2020 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, announces that pre-clinical data on tilvestamab, the
…

Vis børsmeldingen

Company’s novel function blocking, humanized anti-AXL antibody, will be
presented at an ePoster presentation at the virtual 32[nd] EORTC NCI AACR (ENA)
Symposium.

The data presented shows that tilvestamab prevents AXL mediated cell signaling
in cancer cell lines, reduces cell migration and invasion and shows anti-tumor
efficacy in a panel of mouse xenograft models. Further it is shown that in a non
-human primate dose-ranging toxicokinetic study, tilvestamab was well tolerated
during dosing phase up to the highest studied dose of 25mg/kg. Tilvestamab is
currently being evaluated in a Phase I clinical study (BGB149-101; NCT03795142)
in healthy volunteers to evaluate safety, tolerability and pharmacokinetics.

The meeting will run from October 24-25 2020 and will be fully virtual, with
further information available on the ENA
website (https://event.eortc.org/ena2020/). Full details of the abstract are as
follows:

Title: Tilvestamab, a novel clinical stage humanized anti-AXL function blocking
antibody

Date: Saturday, October 24th 2020
Link to
Abstract (https://cm.eortc.org/cmPortal/Searchable/ENA2020/config/normal#!abstrac
tdetails/0000897260)

• END -

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying many life-threatening diseases. In cancer, AXL
suppresses the body’s immune response to tumours and drives cancer treatment
failure across many indications. AXL expression defines a very poor prognosis
subgroup in most cancers. AXL inhibitors, therefore, have potential high value
at the centre of cancer combination therapy, addressing significant unmet
medical needs and multiple high-value market opportunities. Research has also
shown that AXL mediates other aggressive diseases.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potentially first-in-class
selective AXL inhibitor in a broad phase II clinical development programme.
Ongoing clinical trials are investigating bemcentinib in multiple solid and
haematological tumours, in combination with current and emerging therapies
(including immunotherapies, targeted therapies and chemotherapy), and as a
single agent. Bemcentinib targets and binds to the intracellular catalytic
kinase domain of AXL receptor tyrosine kinase and inhibits its activity.
Increase in AXL function has been linked to key mechanisms of drug resistance
and immune escape by tumour cells, leading to aggressive metastatic cancers.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II oncology clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing companion diagnostic tests to identify patient populations most
likely to benefit from bemcentinib: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

Contacts

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[Robnie]

Det må være gode nyheter

[Smania]

AXL Promotes SARS-CoV-2 Infection of Pulmonary and Bronchial Epithelial Cells

De konkluderer med

Taken together, our findings suggest AXL may play an important role in promoting SARS-CoV-2 infection of the human respiratory system and is a potential target in future clinical intervention strategies.

Vel og bra, men så sier de dette i diskusjonsdelen:

As AXL is overexpressed in numerous cancer types, it has already been pursued as a drug target. However, we note that most reported AXL inhibitors target its kinase domain and would thus not have efficacy against SARS-CoV-2 infection because the virus interacts with the extracellular Ig-like domains of AXL ( Figs. 4 g-i ). Alternative approaches include targeting the AXL extracellular Ig-like domains and the region of the SARS-CoV-2 S protein that interacts with AXL. Clinical grade human recombinant soluble AXL may be used to block viral infection ( Figs. 6 c-g ).

Er Bemcentinib av den typen de er skeptiske til (targets the kinase domain)? Noen som kan dette godt nok til å svare?

Svaret her er at ja, bemcentinib er av typen de er skeptiske til. Bemcentinib binder seg til intracellulære kinase-del av AXL, mens covid-19 viruset binder seg en annen plass, utenfor cellen, til Ig-delen av AXL-reseptoren. Imidlertid mener jeg slutningen til kineserne er totalt feil, når de sier at AXL-hemmer som blokkerer kinase-del ikke vil kunne ha effekt mot Covid-19, av den grunn. Forklaringen er at viruset bruker AXL-reseptor til å komme inn i cellen ved hjelp av “apoptotic mimecry”. Den “utgir” seg for å være en død celle, og blir så aktivt tatt opp av cellen den binder seg til, vha AXL. For å aktivere denne prosessen må reseptoren aktiveres, og denne aktiveringen fungerer ikke når kinase-delen er inaktivert. Det nytter ikke for viruset å “henge på” målcellen vha AXL-reseptoren, når bemcentinib hindrer AXL fra å fungere, slik at viruset ikke blir tatt inn i cellen. Bildet under hentet fra BergenBio sin webcast 29.april

COVID-19-Webcast-presentation-29-April-2020.pdf

[Londonmannen]

Se det! Interessant. Og det bidrar ikke akkurat til å redusere mine forventninger til hvilket utkomme vi vil få mhp Bemcentinib sin effekt mot Covid-19. Og den dagen vi eventuelt får en bekreftelse på at Bemcentinib har positiv effekt, da blir det moro å være BgBio aksjonær! Særdeles moro!

[TekBot]

BERGENBIO TO PRESENT CLINICAL TRANSLATIONAL DATA FROM THE ONGOING PHASE II BEMCENTINIB COMBINATION STUDY IN NSCLC AT ANNUAL SITC MEETING

Bergen, Norway, 15 October 2020 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, is pleased to announce that it has been selected for
…

Vis børsmeldingen

an oral presentation at the Society for Immunotherapy of Cancer (SITC) 35[th]
Annual Meeting, taking place online from 9-14 November 2020.

Abstract titles have been announced online
here (https://sitc.sitcancer.org/2020/abstracts/titles/index.php?filter=bemcentin
ib). BerGenBio will present clinical translational research updates from its
Phase II bemcentinib and pembrolizumab combination study (BGBC008) in advanced
non-small cell lung cancer (NSCLC), as part of the Combinatorial Therapies
session on 11[ ]November. Full details of the presentation are below.

Title: A PhII study of bemcentinib, a first-in-class selective AXL kinase
inhibitor, in combination with pembrolizumab in pts with previously-treated
advanced NSCLC: Updated clinical & translational analysis

Author: Professor James Spicer, Professor of Experimental Cancer Medicine at
King’s College London

Session/Abstract ID: Combinatorial Therapies, 362

Date/Time: 11 November 2020, 11.40am EST

The presentation will be made available on BerGenBio’s website, under
‘Presentations (https://www.bergenbio.com/investors/presentations/)’.

• END -

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying life-threatening diseases. In cancer, AXL
suppresses the body’s immune response to tumours and drives cancer treatment
failure across many indications. AXL expression defines a very poor prognosis
subgroup in most cancers. AXL inhibitors, therefore, have potential high value
at the centre of cancer combination therapy, addressing significant unmet
medical needs and multiple high-value market opportunities. Research has also
shown that AXL mediates other aggressive diseases.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potentially first-in-class
selective AXL inhibitor in a broad phase II clinical development programme.
Ongoing clinical trials are investigating bemcentinib in multiple solid and
haematological tumours, in combination with current and emerging therapies
(including immunotherapies, targeted therapies and chemotherapy), and as a
single agent. Bemcentinib targets and binds to the intracellular catalytic
kinase domain of AXL receptor tyrosine kinase and inhibits its activity.
Increase in AXL function has been linked to key mechanisms of drug resistance
and immune escape by tumour cells, leading to aggressive metastatic cancers.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II oncology clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing companion diagnostic tests to identify patient populations most
likely to benefit from bemcentinib: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

Contacts

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[larosaleda]

2 abstrakter fra databasen til WHO som jeg finner interessante. Er noe uklart når de blev lagt til men jeg finner de ikke i tråden og det er ikke mindre aktuellt nå som “solidarity” vurderer nye kandidater. Bemcentinib er nevnt i begge:

Elevated AXL expression following SARS-CoV-2 infection in non-small cell lung...

SARS-CoV-2 infection induces EMT-like molecular changes, including...

[TekBot]

BERGENBIO CONFIRMS FIRST PATIENT ENROLLED IN PHASE II TRIAL ASSESSING BEMCENTINIB AS A POTENTIAL TREATMENT FOR COVID-19 PATIENTS IN SOUTH AFRICA

Bergen, Norway - 21 October 2020: BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, today announces that the first patient has
…

Vis børsmeldingen

been enrolled in the company sponsored Phase II clinical trial (BGBC020),
assessing the efficacy and safety of bemcentinib for the treatment of
hospitalised COVID-19 patients in South Africa and India.

The Phase II study will recruit 120 hospitalised COVID-19 patients across five
sites in South Africa and seven sites in India. 60 patients will receive
bemcentinib (as monotherapy or in combination with standard of care medication)
and 60 patients in a control group (receiving standard of care treatment only).

The primary endpoint of the trial will be time to clinical improvement of at
least two points (from randomisation) on a nine-point ordinal scale, or live
discharge from the hospital, whichever comes first. The trial protocol will
permit co-administration with other medicines recommended for treatment of COVID
-19, including remdesivir and dexamethasone. A Data Monitoring Committee (DMC)
formed of a group of independent experts external to the study has been
established. The DMC will assess the progress, safety data and, critical
efficacy endpoints of the trial as it proceeds.

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “We
are excited to continue exploring the profile of bemcentinib as a potential
treatment for hospitalised COVID-19 patients and are delighted to announce
that the study has commenced in South Africa. The region remains a geographical
location of high incidence and we look forward to
accelerating recruitment in South Africa and India, and providing further
updates on our progress in due course.”

• END -

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying many life-threatening diseases. In cancer, AXL
suppresses the body’s immune response to tumours and drives cancer treatment
failure across many indications. AXL expression defines a very poor prognosis
subgroup in most cancers. AXL inhibitors, therefore, have potential high value
at the centre of cancer combination therapy, addressing significant unmet
medical needs and multiple high-value market opportunities. Research has also
shown that AXL mediates other aggressive diseases.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potentially first-in-class
selective AXL inhibitor in a broad phase II clinical development programme.
Ongoing clinical trials are investigating bemcentinib in multiple solid and
haematological tumours, in combination with current and emerging therapies
(including immunotherapies, targeted therapies and chemotherapy), and as a
single agent. Bemcentinib targets and binds to the intracellular catalytic
kinase domain of AXL receptor tyrosine kinase and inhibits its activity.
Increase in AXL function has been linked to key mechanisms of drug resistance
and immune escape by tumour cells, leading to aggressive metastatic cancers.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II oncology clinical development
programme focused on combination and single agent therapy in lung
cancer, leukaemia and COVID-19. A first-in-class functional blocking anti-AXL
antibody, tilvestamab, is undergoing phase I clinical testing. In parallel,
BerGenBio is developing companion diagnostic tests to identify patient
populations most likely to benefit from bemcentinib: this is expected to
facilitate more efficient registration trials supporting a precision medicine
-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Contacts

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BERGENBIO VIRTUAL R&D DAY - 06 NOVEMBER 2020

Bergen, Norway, 23[rd] October 2020 - BerGenBio ASA (OSE:BGBIO), a clinical
-stage biopharmaceutical company developing novel, selective AXL kinase
inhibitors for severe unmet medical need, is pleased to announce that it will
…

Vis børsmeldingen

host a virtual R&D Day on 06 November 2020 from 13.00 CET.

The event will feature independent experts highlighting the role of AXL kinase
as an essential mediator of the biological mechanisms underlying life
-threatening diseases. The presentations will focus on the role of AXL in
specific disease areas including oncology, fibrosis and infectious disease such
as COVID-19. Each presentation will be followed by a Q&A session.

A preliminary program for the event is outlined below. To register, please click
here (bergenbio@consilium
-comms.com?subject=I%20would%20like%20to%20attend%20the%20BerGenBio%20Virtual%20E
vent).

              Preliminary Agenda
                (times in CET)

13:00 Introduction - Richard
Godfrey, Chief Executive
Officer, BerGenBio

13:10 AXL in AML/MDS
- Professor Sonja
Loges, Director,
Department
of Personalised Oncology,
University Hospital
Mannheim and Division
of Personalised Medical
Oncology, German Research
Center - DKFZ
(Heidelberg, Germany)
13:40 AXL in lung cancer - Dr
Matthew Krebs, Clinical
Senior Lecturer in
Experimental Cancer
Medicine and Honorary
Consultant in Medical
Oncology, The Christie
NHS Foundation Trust
(Manchester, UK)
14:10 AXL and viruses/COVID-19
- Professor Wendy Maury,
Professor of Microbiology
and Immunology,
University of Iowa (Iowa
City, USA)
14:40 AXL in fibrosis/IPF -
Professor Cory Hogaboam,
Professor of Medicine,
Cedars-Sinai Medical
Center (Los Angeles, USA)
15:10 Bemcentinib clinical
development plan - Hani
Gabra, Chief Medical
Officer, BerGenBio
15:25 Concluding remarks -
Richard Godfrey, Chief
Executive Officer,
BerGenBio
For further information, please contact Consilium
Strategic Communications at bergenbio@consilium
-comms.com or
i (ir@bergenbio.com)r@bergenbio.co (ir@bergenbio.com)m

• END -

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying life-threatening diseases. In cancer, AXL
suppresses the body’s immune response to tumours and drives cancer treatment
failure across many indications. AXL expression defines a very poor prognosis
subgroup in most cancers. AXL inhibitors, therefore, have potential high value
at the centre of cancer combination therapy, addressing significant unmet
medical needs and multiple high-value market opportunities. Research has also
shown that AXL mediates other aggressive diseases.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potentially first-in-class
selective AXL inhibitor in a broad phase II clinical development programme.
Ongoing clinical trials are investigating bemcentinib in multiple solid and
haematological tumours, in combination with current and emerging therapies
(including immunotherapies, targeted therapies and chemotherapy), and as a
single agent. Bemcentinib targets and binds to the intracellular catalytic
kinase domain of AXL receptor tyrosine kinase and inhibits its activity.
Increase in AXL function has been linked to key mechanisms of drug resistance
and immune escape by tumour cells, leading to aggressive metastatic cancers.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing a companion diagnostic test to identify patient populations most
likely to benefit from bemcentinib: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

Contacts

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde